Sickle cell experts speak during a STAT event during the ASH 2024 conference in San Diego.
Sickle cell experts speak at a STAT event during the ASH 2024 conference in San Diego. From left, they are Texas Children’s Hospital physician Titilope Fasipe, University of Alabama at Birmingham professor Julie Kanter, and Teonna Woolford, co-founder of the Sickle Cell Reproductive Health Education Directive.Arlene Ibarra for STAT

SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a panel discussion among sickle cell experts Saturday at STAT@ASH, which took place during the American Society of Hematology’s annual meeting.

They said patients were despondent over how suddenly the drug was pulled from the market in September because there had been no clear indication of problems in advance of the announcement. The speakers added that pharmaceutical executives should have worked more closely with specialists and sickle cell centers of excellence to roll out the drug to the right patients in the first place. 

advertisement

The drug was “given out like water” and its rollout was highly profit-driven, with little understanding of the specific needs of a vulnerable and genetically diverse patient population, said Julie Kanter, a leading sickle cell expert at the University of Alabama at Birmingham. At the time of the initial rollout, the drug was owned by the biotech company Global Blood Therapeutics. Pfizer later acquired the company.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe